Low-dose isoflavone aglycone alleviates psychological symptoms of menopause in Japanese women: a randomized, double-blind, placebo-controlled study

Hirose, Asuka; Terauchi, Masakazu; Akiyoshi, Mihoko; Owa, Yoko; Kato, Kiyoko; Kubota, Toshiro

doi:10.1007/s00404-015-3849-0

Cited by 54 publications

(75 citation statements)

References 41 publications

(39 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…94 In contrast to the benefit of this dose, this eight-week trial found that a very low dose of isoflavones (12.5 mg/d) lacked efficacy. It is noteworthy that isoflavone exposure occurred via treatment and as a result of a likely background dietary intake of about 40 mg/d.…”

Section: Introductionmentioning

confidence: 81%

“…Of the 20 trials in Table 1 that evaluated the mood and anti-depressant effects of isoflavones (or an isoflavone metabolite), nine found evidence of efficacy, 94,98,100-102,104,109,110,112 and a tenth found benefit at one dose but not another. 97 In addition to these ten trials the findings from one other trial are suggestive of benefit when considering the relatively low intervention dose and short study duration.…”

Section: Discussionmentioning

confidence: 99%

“…The dose of isoflavones ranged from 12.5 94 to 120 mg/d 95 and the duration from six weeks 96,97 to two years. 95,98 Sixteen trials 94-108 utilized a parallel design, three a cross-over design 109-111 and one was open label study. 112 Only one of the 20 trials involved clinically depressed patients.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Evaluation of the potential antidepressant effects of soybean isoflavones

Messina

Gleason²

2016

Menopause

View full text Add to dashboard Cite

Objective To determine whether isoflavones affect depressive symptoms in women. Methods Literature searches were conducted to identify clinical and epidemiologic studies that evaluated the impact of soy intake and isoflavone exposure on depressive symptoms. References from identified studies were also evaluated to identify eligible studies. Results Only limited epidemiologic research has evaluated the impact of soy or isoflavone intake on depression although several studies from China and Japan did find soy product intake was inversely related to risk of depression. However, often times, soy was evaluated only as a component of a summative dietary pattern (e.g., a “Japanese” or “Healthy” diet). Of the 20 intervention studies identified, roughly half found statistically significant reductions in depressive symptoms in response to isoflavones although several had design weakness. Of those studies reporting a lack of antidepressant effects of isoflavones, design limitations likely contributed to the lack of efficacy. In all but two trials, assessment of depression was, however, a secondary outcome. It is notable that both trials in which depression was a primary outcome found isoflavones significantly improved symptoms. Conclusions Although the data are inconsistent and limited, the clinical and epidemiologic evidence suggests that isoflavones may offer a safe, well-tolerated option for management of depression. Furthermore, the intervention doses used in the clinical studies fall well within the dietary range. The extant literature reveals key design features for future studies, which based upon the results of this review, are clearly warranted.

show abstract

Section: Introductionmentioning

confidence: 81%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Evaluation of the potential antidepressant effects of soybean isoflavones

Messina

Gleason²

2016

Menopause

View full text Add to dashboard Cite

show abstract

“…For example, over a two-year period, an Italian study that was evaluating mood effects, found that postmenopausal women taking 54 mg/day genistein showed a decline in depressive symptoms as measured by the Zung Self-rating Depression Scale whereas no change occurred in the placebo group [330]. Also, a Japanese study involving peri- and postmenopausal women found that a very moderate dose (25 mg/day) of isoflavones consumed in aglycone form reduced depressive symptoms as assessed by the Hospital Anxiety and Depression Scale and also reduced anxiety as assessed by the Athens Insomnia Scale [331]. In contrast to the benefit of this dose, this eight-week trial found that a very low dose of isoflavones (12.5 mg/day) lacked efficacy.…”

Section: Mental Healthmentioning

confidence: 99%

Soy and Health Update: Evaluation of the Clinical and Epidemiologic Literature

2016

View full text Add to dashboard Cite

Soyfoods have long been recognized as sources of high-quality protein and healthful fat, but over the past 25 years these foods have been rigorously investigated for their role in chronic disease prevention and treatment. There is evidence, for example, that they reduce risk of coronary heart disease and breast and prostate cancer. In addition, soy alleviates hot flashes and may favorably affect renal function, alleviate depressive symptoms and improve skin health. Much of the focus on soyfoods is because they are uniquely-rich sources of isoflavones. Isoflavones are classified as both phytoestrogens and selective estrogen receptor modulators. Despite the many proposed benefits, the presence of isoflavones has led to concerns that soy may exert untoward effects in some individuals. However, these concerns are based primarily on animal studies, whereas the human research supports the safety and benefits of soyfoods. In support of safety is the recent conclusion of the European Food Safety Authority that isoflavones do not adversely affect the breast, thyroid or uterus of postmenopausal women. This review covers each of the major research areas involving soy focusing primarily on the clinical and epidemiologic research. Background information on Asian soy intake, isoflavones, and nutrient content is also provided.

show abstract

“…A daidzein metabolizmusának lépései [20] ÖSSZEFOGLALÓ KÖZLEMÉNY Az izoflavonoidok 25 mg dózisban már szignifikánsan csökkentették a depressziós tüneteket és az alvászavart is, emellett a Menopauza Skála értékeiben is szignifikáns javulást regisztráltak [24].…”

Section: áBraunclassified

Fitoösztrogének a menopauza terápiájában

Remport

Blázovics

2017

Orvosi Hetilap

View full text Add to dashboard Cite

A korábbi évszázadokban a társadalmi és gazdasági körülmények, az orvostudomány hiányosságai, a járványok és a háborúk miatt rövid volt a várható élettartam, így a nők többsége meg sem érte a változókort. Napjainkban a fejlett országokban az emberek átlagosan 75-80 éves korukig élnek, az átlagéletkor kitolódásával nő a menopauzában érin-tettek, illetve a menopauzában töltött évek száma, mára már a nők életük harmadát menopauzában töltik. A kellemetlen tünetek kezelésének egyetlen hatékony módját évszázadokon át a gyógynövények alkalmazása jelentette, amely ismeret szájhagyomány útján terjedt. A XX. században a szintetikus gyógyszergyártás kialakulásával és a hormonpótló kezelés bevezetésével ez a terápiás forma háttérbe szorult. A média hatására a XX. században kialakult az a társadalmi igény a nők körében, hogy minél tovább megőrizzék szépségüket és fiatalságukat. A hormonpótló terápia nagy népszerűségnek örvendett, mert a nők átmenetileg megszabadultak életminőségüket rontó tüneteiktől, viszont évekkel később kiderült, hogy a hormonpótlás komoly veszélyekkel járhat. A gyógynövényes terápiáknak határozott előnye a hormonpótló kezelésben használt szintetikumokkal szemben a kedvezőbb mellékhatásprofil. A nők ezért ismét szívesen fordulnak a bevált természetes gyógymódokhoz. Egyre növekszik az érdeklődés a gyógynövénytartal-mú készítmények iránt. A fitoösztrogének hatásának tanulmányozása mára már a kutatások aktív területévé vált. Az állatokon és embereken végzett vizsgálatok eredményei azonban ellentmondásosak, egyes források szerint a fitoöszt-rogének hatékonynak és biztonságosnak bizonyulnak, más szerzők szerint hatástalanok menopauzában vagy kifejezetten veszélyesek, nem ajánlhatók mindenkinek. A nők testi, mentális egészsége és biztonsága érdekében fontos ezzel a kérdéssel foglalkozni, alkalmazásuk előtt ezért szükséges felmérni az előnyöket és a rizikót. Orv Hetil. 2017; 158(32): 1243-1251.Kulcsszavak: menopauza, hormonpótló kezelés, fitoösztrogének, izoflavonoidok, szója Phytoestrogens in the treatment of menopauseIn previous centuries many women did not even live until their menopause years due to poor economic conditions, deficiencies of medicine, epidemics and wars. Nowadays in the developed countries, people live until they are 75-80 years old, and with the expansion of average age, the number of people affected by menopause and the years spent in that state increase. Nowadays women spend one third of their lives in the menopausal stage. The only effective way to treat unpleasant symptoms for centuries was with the use of herbs, and the knowledge about them spread through oral tradition. In the 20th century, this therapeutic form was pushed into the background by the development of synthetic drug production and the introduction of hormone replacement therapy. Thanks to the influence of media in the 20th century, women began to have the social need for preserving their beauty and youth for as long as they could. Hormone replacement therapy enjoyed great popularity because women were temporarily relieved...

show abstract

Low-dose isoflavone aglycone alleviates psychological symptoms of menopause in Japanese women: a randomized, double-blind, placebo-controlled study

Cited by 54 publications

References 41 publications

Evaluation of the potential antidepressant effects of soybean isoflavones

Evaluation of the potential antidepressant effects of soybean isoflavones

Soy and Health Update: Evaluation of the Clinical and Epidemiologic Literature

Fitoösztrogének a menopauza terápiájában

Contact Info

Product

Resources

About